The key contribution of IL-5 to the enhanced eosinophil activation in EA is supported by the effect of mepolizumab as a clinical treatment, which not only reduced eosinophil counts in blood and airways but also reduced pro-inflammatory capacity of eosinophils in eosinophilic patients. The gene discussed is IL5; the disease is Esophageal atresia.